A DNA vaccine for the prevention of Ebola virus infection.
The NIH and Vical Inc are developing an intramuscular needle-free DNA vaccine containing plasmids encoding the envelope glycoprotein of Ebola virus (EBOV) from the Sudan and Zaire strains, and the nucleoprotein of EBOV Zaire strain. A phase I clinical trial demonstrated a good safety profile, with most adverse events limited to the site of injection and largely attributable to the delivery.
Tulane University Health Sciences Center, Department of Medicine, Infectious Diseases Section, 1430 Tulane Ave SL-87, New Orleans, LA 70112-2699, USA. email@example.com
SourceCurrent opinion in molecular therapeutics 10:3 2008 Jun pg 285-93
MeSHClinical Trials as Topic
Drug Evaluation, Preclinical
Hemorrhagic Fever, Ebola
Pub Type(s)Journal Article